Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: November 30, 2008 (Fiscal Year 2009, Q2)
Business Overview: AngioDynamics designs, develops, and markets medical devices for minimally invasive, image-guided procedures, primarily treating peripheral vascular disease and local oncology. Beginning with fiscal 2009, the company reorganized into three reportable segments: Peripheral Vascular, Access, and Oncology/Surgery.
Key Financial Metrics
| Metric | Three Months Ended Nov 30, 2008 | Six Months Ended Nov 30, 2008 |
|---|---|---|
| Net Sales | $48.5 million | $92.8 million |
| Gross Profit | $29.7 million (61.3% margin) | $57.2 million (61.6% margin) |
| Operating Income | $4.9 million (10.1% margin) | $8.7 million (9.4% margin) |
| Net Income | $2.9 million | $5.1 million |
| Diluted EPS | $0.12 | $0.21 |
| Cash & Cash Equivalents | $19.7 million (as of Nov 30, 2008) | |
| Total Cash, Equivalents & Marketable Securities | $57.8 million (as of Nov 30, 2008) | |
| Total Debt | $7.2 million (as of Nov 30, 2008) | |
| Operating Cash Flow (6 months) | $6.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% year-over-year for both the quarter and six-month periods. This growth was driven primarily by the acquisition of Diomed assets (contributing ~$5.6 million in the quarter and ~$8.8 million in the six months) and increased unit sales of LC Bead and SmartPort CT products.
- Profitability: While revenue grew, net income decreased slightly ($2.9M vs $3.1M for the quarter; $5.1M vs $5.5M for six months). This was due to increased operating expenses, specifically R&D and Sales & Marketing, and higher amortization of intangibles from recent acquisitions.
- Expense Increases:
- R&D expenses rose 20% (quarter) and 31% (six months) to support the development and commercialization of Irreversible Electroporation (IRE) technology.
- Sales and Marketing expenses increased 24% due to expanded sales territories, Diomed integration, and IRE marketing.
- Amortization of intangibles increased significantly due to the Oncobionic and Diomed acquisitions.
- Liquidity: Cash and cash equivalents decreased from $32.0 million to $19.7 million. Total debt decreased from $17.1 million to $7.2 million following the repayment of $9.7 million in convertible notes assumed in the RITA acquisition.
- Segment Performance: Peripheral Vascular sales grew 33% (quarter) and 32% (six months). Oncology/Surgery sales grew 13% (quarter) and 15% (six months). The Oncology/Surgery segment reported an operating loss of $1.1 million for the quarter.
Guidance, Outlook, and Risks
- Acquisitions: The company completed the acquisition of Diomed assets (June 2008) and Oncobionic, Inc. (May 2008). The Oncobionic acquisition includes a remaining $5.0 million payment due in November 2009 and future royalty obligations on IRE technology sales.
- R&D Outlook: Management expects R&D expenditures to remain approximately 9% of net sales for fiscal 2009 and beyond, driven by continued investment in IRE technology.
- Liquidity Outlook: Management believes current cash balances and operating cash flow are sufficient to meet needs for the next 12 months. However, significant future acquisitions will likely require additional equity or debt financing.
- Market Risks:
- Auction Rate Securities (ARS): The company holds $1.85 million in ARS issued by New York state agencies that have experienced failed auctions. While interest payments are current, there is a risk of inability to liquidate these positions in the near term.
- Interest Rate Risk: The company has variable rate financing of $7.2 million, partially hedged via interest rate swaps.
- Foreign Exchange: Approximately 11% of sales are international; strengthening of the US dollar contributed to foreign exchange losses.
- Tax Benefits: The effective tax rate benefited from the retroactive extension of R&D tax credits via the "Tax Extenders and Alternative Minimum Tax Relief Act of 2008."
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and integration costs associated with the Diomed and Oncobionic acquisitions.
- IRE Technology Commercialization: Assess the progress and sales trajectory of the NanoKnife generator and IRE technology, which is driving increased R&D spend.
- Auction Rate Securities Exposure: Confirm the current status and liquidity risk of the $1.85 million investment in failed auction rate securities.
- Debt Covenants: Review the financial covenants related to the IDA agreements and Notes, which collateralize substantially all company assets.
- Segment Margins: Monitor the operating loss in the Oncology/Surgery segment and the impact of amortization on overall profitability.